A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.

Abstract

INTRODUCTION This phase I/IIA study evaluated the maximum-tolerated dose (MTD), safety, and clinical benefit of pomalidomide, an immunomodulatory drug (IMiD), combined with cisplatin+etoposide chemotherapy, in treatment-naive patients with extensive-stage (ES) small-cell lung cancer (SCLC). METHODS In this multicenter, open-label, dose-escalation study… (More)
DOI: 10.1097/JTO.0b013e318282707b

Topics

  • Presentations referencing similar topics